

LISTING OF THE CLAIMS:

Claims 1-6 (Canceled)

Claim 7 (Currently Amended): A conjugate of a cytostatic compound and ~~transferrin or albumin~~ or a polyethylene glycol, wherein:


- (a) said cytostatic compound is coupled via a spacer comprising a group which is derived from a maleinimido group, ~~to thiolated transferrin or thiolated albumin~~ or to polyethylene glycol having at least one HS or H₂N group; or
- (b) ~~2 to 30 equivalents of said cytostatic compound are each coupled via a spacer comprising a group which is derived from a maleinimido group, to thiolated albumin, wherein the thiolated albumin is conjugated via a group which is derived from a bismaleinimido compound to transferrin or a monoclonal antibody which is directed to a tumor associated antigen; and~~

wherein ~~said thiolated transferrin or said thiolated albumin has 1 to 30 HS groups on the average,~~
~~and~~ said polyethylene glycol has a mass of about between 5,000 and 200,000 Da.


Claim 8 (Previously Presented): The conjugate according to claim 7, wherein said cytostatic compound is selected from the group consisting of anthracyclines, nitrogen mustard gas derivatives, purine or pyrimidine antagonists, folic acid antagonists, taxoids, camptothecines, podophyllotoxin derivatives, vinca alkaloids and *cis*-configured platinum(II)-complexes.

Claim 9 (Previously Presented): The conjugate according to claim 7, wherein said cytostatic compound is selected from the group consisting of doxorubicine, daunorubicine, epirubicine, idarubicine, mitoxandrone, chloroambucil, melphalan, 5-fluorouracil, 5'-deoxy-5-fluorouridine, thioguanine, methotrexate, paclitaxel, docetaxel, topotecane, 9-aminocamptothecine, etoposide, teniposide, mitopodozide, vinblastine, vincristine, vindesine, vinorelbine and compounds of the general formulas I, II, III or IV:


Formula I




Formula II



Formula III




Formula IV




wherein $n = 0-6$, $X = -\text{NH}_2$, $-\text{OH}$, $-\text{COOH}$, $-\text{O}-\text{CO}-\text{R}-\text{COR}^*$ or $-\text{NH}-\text{CO}-\text{R}-\text{COR}^*$, wherein R is an aliphatic carbon chain having 1-6 carbon atoms or is a substituted or unsubstituted phenylene group and R^* is H, phenyl or alkyl having 1-6 carbon atoms.

Claim 10 (Currently Amended): The conjugate according to claim 7, wherein said cytostatic compound having said spacer comprising a group which is derived from a maleinimido group, is formed through reaction of said cytostatic compound with a maleinimide compound of the formula V, VI or VII:


Formula V



Formula VI



Formula VII



~~wherein,~~ wherein R is an aliphatic carbon chain having 1-6 carbon atoms or a substituted or unsubstituted benzyl group or a substituted or unsubstituted phenylene group, Y = -OH, -COOH, -COCl, -CONH-(CH₂)_n-OH, -COO-(CH₂)_n-NH₂, -COO-(CH₂)_n-NHNH₂, -SO₃H, -SO₃Cl, -SO₂-NHNH₂, -O-COCl, -CHO or -COR*, wherein n = 1-6 and R* represents H, phenyl or alkyl having 1-6 carbon atoms, and

the thus obtained maleinimide derivative of said cytostatic compound is coupled to ~~said thiolated albumin or said thiolated transferrin or~~ said polyethylene glycol, wherein the chemical linkage between said cytostatic compound and said maleinimide compound occurs through an amide, ester, imine, hydrazone, carboxyl hydrazone, oxycarbonyl, acetal or ketal bond.

Claim 11 (Currently Amended): A method for the production of a conjugate of a ~~cytostatic compound and transferrin or albumin or~~ a polyethylene glycol according to claim 7, comprising the steps of:

- (a) reacting a cytostatic compound with a maleinimide compound, such that maleinimide derivatives of said cytostatic compound are produced, wherein the chemical linkage between said cytostatic compound and said maleinimide compound occurs through an amide, ester, imine, hydrazone, carboxyl hydrazone, oxycarbonyl, acetal or ketal bond; and
- (b) (i) coupling said maleinimide derivative obtained in step (a) of the cytostatic compound to ~~thiolated transferrin or albumin having 1 to 30 HS groups~~

~~on the average or to~~ polyethylene glycol having at least one HS or H₂N group and having a mass of about between 5,000 and 200,000 Da; ~~or~~
(ii) ~~loading thiolated albumin with 2 to 30 equivalents of said maleinimide derivatives obtained in step (a) of the cytostatic compound and conjugating with transferrin or a monoclonal antibody directed to a tumor-associated antigen via a group which is derived from a bismaleinimido compound.~~

Claim 12 (Previously Presented): A pharmaceutical composition, comprising the conjugate according to claim 7, optionally together with carriers and auxiliary agents.

Claim 13 (Previously Presented): Method for the treatment of a cancer disease, comprising the step of treating an organism having a cancer disease with the conjugate of claim 7.

Claim 14 (Previously Presented): Method according to claim 13, wherein said cancer disease comprises bladder, lung, mamma, melanoma or prostate carcinomas.